PURPOSE: Mismatch repair deficiency (dMMR) or microsatellite instability (MSI) represents a distinct phenotype among solid tumors resulting in the generation of highly immunogenic neoantigens. Pembrolizumab has been approved in first-line unresectable or metastatic dMMR/MSI colorectal cancers (CRC). We aimed to assess efficacy and tolerance of perioperative pembrolizumab in dMMR/MSI CRC. PATIENTS AND METHODS: The prospective multicenter phase II trial IMHOTEP enrolled patients with localized resectable dMMR/MSI CRC to receive one or two cycles of IV pembrolizumab 400 mg once every 6 weeks before surgery and 1-year total duration thereafter. The primary end point was pathologic complete response (pCR) rate (ypT0N0). Secondary objectives included safety, event-free survival, and overall survival. RESULTS: IMHOTEP enrolled 81 patients with dMMR/MSI CRC who received at least one cycle of pembrolizumab from November 26, 2021, to February 22, 2023: median age was 66 (21-89) years, 46 (52%) were women, and 63 (71%) had clinical stage III disease at baseline. Out of the 72 patients included in the efficacy population, 38 patients (52.7% [95% CI, 41.4 to 63.9]) achieved a pCR. The exploratory post hoc analysis showed a pCR rate increased from 46% (23/50) after one cycle to 68.2% (15/22) after two cycles of neoadjuvant pembrolizumab ( P = .0125). With a median follow-up of 24.5 (95% CI, 23.3 to 25.6) months, three disease recurrences occurred. Grade ≥3 immune-related toxicities were reported in 14 (15.7%) patients including one grade 5 (myasthenia). CONCLUSION: The IMHOTEP trial showed promising results, with pCR achieved after one or two cycles of neoadjuvant pembrolizumab in 53% of patients with dMMR/MSI CRC. To our knowledge, this prospective study is the first to demonstrate the feasibility and the safety of perioperative pembrolizumab.
Combining immunotherapy with chemoradiation is effective in locally advanced cervical cancer. However, the impact of induction combination immunotherapy on immune modulation and treatment response is poorly understood. In this phase II trial (NCT04256213), 40 females with locally advanced cervical carcinoma received one cycle of nivolumab-plus-ipilimumab immunotherapy before standard chemoradiation, followed by maintenance nivolumab. We show, using multiplex-immunofluorescence tissue imaging, a significantly increased CD8+/FOXP3+ cell ratio (primary endpoint; increase of 0.87 cells/mm², P = 0.0164) and proliferative CD8+ T-cell density after one cycle of combination immunotherapy. HOT score (27-gene-based signature identifying immunologically active tumors) also increased significantly (exploratory analysis; 0.17, P < 0.0001). Objective response rates (secondary endpoint) were 13% immediately after combination immunotherapy, 98% (65% complete response) after chemoradiation, and 90% at treatment completion. High HOT score at baseline and immune changes induced by combination immunotherapy were associated with complete response at treatment completion. Induction immunotherapy may prime tumors for improved response to standard therapy.
12 August 2026 in ESMO Real World Data and Digital Oncology
Patients with localized mismatch repair deficient (dMMR)/microsatellite instability (MSI)-high esophagogastric adenocarcinomas are rare and derive limited benefit from standard perioperative chemotherapy. Immune checkpoint inhibitors have demonstrated efficacy in metastatic dMMR/MSI tumors, and recent phase II studies have shown promising activity in localized stages. The multicenter, phase II trial IMHOTEP (NCT04795661) assessed perioperative pembrolizumab in nonmetastatic dMMR/MSI solid tumors. The esophagogastric cohort included patients with localized (cT2-4N0/N+M0) esophagogastric cancer and confirmed dMMR/MSI status. Patients received one or two infusions of neoadjuvant pembrolizumab (400 mg every 6 weeks) and optional post-operative pembrolizumab for up to nine cycles and were candidates for surgery. The primary endpoint was pathological complete response (pCR; ypT0N0). Between May 2021 and February 2025, among the 41 patients treated with pembrolizumab, 36 received one to two neoadjuvant pembrolizumab infusions and were eligible for surgery and included in the efficacy analysis (surgery: N = 27; no surgery: N = 9). Of note, five patients were excluded from efficacy analysis (inclusion/exclusion criteria not met, N = 3; >2 neoadjuvant pembrolizumab: N = 2). The subgroup of operated patients had R0 resection (N = 27), and four (14.8%) achieved pCR. With a median follow-up of 25.8 months, 25 (93%) patients experienced no progression, recurrence, or death. Grade ≥3 treatment-related adverse events occurred in nine (22%) patients. Perioperative pembrolizumab is feasible and safe in localized dMMR/MSI esophagogastric cancers. Further investigation is warranted to optimize the duration and nature of neoadjuvant immunotherapy.